ACCC COVID-19 Resource Center & Listserv
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for Colorado's MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 1991
Meetings & Education
RMOS Educational Award
State & Federal Resources
Off-Label Use Literature
Patient Advocacy Organizations
National Professional Organizations
RMOS Corporate Members
Become a Corporate Member
Industry News Archive
FDA Approves Selinexor for Multiple Myeloma
On July 3, 2019, the U.S. Food and Drug Administration (FDA) granted accelerated approval to selinexor (Xpovio, Karyopharm Therapeutics) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
As a condition of accelerated approval, further clinical trials may be required to verify and describe selinexor’s benefit. FDA granted this application fast track designation and orphan drug designation.
Read FDA announcement
Tweets by OSSatACCC